Chemotherapy in Inflammatory Breast Cancer

  • Claudia Arce-SalinasEmail author
  • Flavia Morales-Vasquez
  • Fernando Lara-Medina
  • Silvia Patricia Villarreal-Colin


Inflammatory breast cancer has poor prognosis. Without systemic therapy, the 5-year survival was 4 %. Since 1970s, with the introduction of neoadjuvant chemotherapy in the treatment of this tumor, the prognosis has changed. The first attempt of systemic therapy was done with 5-FU given for long time but with improvement in DFS. Later, the incorporation of chemoimmunotherapy based on BCG, however, due to the lack of specificity and the same results without BCG, this modality was abandoned. Finally, regimens based on anthracyclines and taxanes have become the standard of care, not to mention the importance of multimodal treatment.


Overall Survival Autologous Stem Cell Transplantation Inflammatory Breast Cancer Locally Advanced Breast Cancer Optimal Local Control 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Wang CC, Griscom NT. Inflammatory carcinoma of the breast. Results following orthovoltage and supervoltage radiation therapy. Clin Radiol. 1964;15:167–74.PubMedCrossRefGoogle Scholar
  2. 2.
    Kell MR, Morrow M. Surgical aspects of inflammatory breast cancer. Breast Dis. 2005;22:67–73.PubMedGoogle Scholar
  3. 3.
    Bozzetti F, Saccozzi R, De Lena M, Salvadori B. Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol. 1981;18:355–61.PubMedCrossRefGoogle Scholar
  4. 4.
    De la Garza J, de la Huerta R, Torres R, Sánchez-Basurto C. Different management of inflammatory carcinoma, ASCO Meeting. Denver; 1977 Abstract C-32.Google Scholar
  5. 5.
    De la Garza J. Cáncer inflamatorio de la glándula mamaria. Experiencia de 6 años con QT. RT. Cir Ciruj. 1977;45(6):351–7.Google Scholar
  6. 6.
    Barker JL, Montague E, Peters LJ. Clinical experience with irradiation of inflammatory carcinoma of the breast with or without elective chemotherapy. Cancer. 1980;45:625–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Zytherberg B, Salat-Baroux J, Ravina JH, et al. Intial Chemoimmunotheropy in inflammatory cancinoma of the breast cancer 1982:IS:1537-43Google Scholar
  8. 8.
    Israel L, Breau JL, Morere JF. Two years of high-dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. A phase II study of 25 cases with a median follow-up of 35 months. Cancer. 1986;57:24–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Hanna MG, Zbar B, Rapp HJ. Histopathology of tumor regression after intralesional injection of mycobacterium bovis. I. Tumor growth and metastases. J Natl Cancer Inst. 1972;48:1441–55.PubMedGoogle Scholar
  10. 10.
    Zbar B, Tanaka T. Immunotherapy of cancer: regression of tumors after intralesional injection of Mycobacterium bovis. Science. 1971;772:271–3.CrossRefGoogle Scholar
  11. 11.
    Wiseman C, Jessup JM, Smith TL, et al. Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor CelVBCG immunotherapy. Cancer. 1982;49:1266–71.PubMedCrossRefGoogle Scholar
  12. 12.
    Ueno NT, Buzdar AU, Singletary SE, et al. Combined- modality treatment of inflammatory breast carcinoma: twenty years of experience at MD Anderson cancer center. Cancer Chemother Pharmacol. 1997;40:321–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993;16:223–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Veyret C, Levy CH, Chollet PH, et al. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy. Ten-year results from the French Adjuvant Study Group GETIS 02 trial. Cancer. 2006;107:2535–44.PubMedCrossRefGoogle Scholar
  15. 15.
    Maloisel F, Dufour P, Bergerat JP, et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer. 1990;65:851–5.PubMedCrossRefGoogle Scholar
  16. 16.
    De Boer RH, Allum WH, Ebbs SR, et al. Multimodality therapy in inflammatory breast cancer: is there a place for surgery? Ann Oncol. 2000;11:1147–53.PubMedCrossRefGoogle Scholar
  17. 17.
    Cristofanilli M, Buzdar AU, Sneige N, et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001;92:1775–82.PubMedCrossRefGoogle Scholar
  18. 18.
    Dan Costa S, Sibylle L, Kaufmann M, et al. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol. 2009;28:83–91.CrossRefGoogle Scholar
  19. 19.
    Harris EE, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003;55:1200–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Cristofanilli M, González-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the MD Anderson cancer center experience. Clin Breast Cancer. 2004;4:415–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004;22:4067–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Evans TR, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo Celtic Cooperative Oncology Group study. J Clin Oncol. 2005;23:2988–95.PubMedCrossRefGoogle Scholar
  23. 23.
    Yang CH, Cristofanilli M. Systemic treatments for inflammatory breast cancer. Breast Dis. 2005;22:55–65.PubMedGoogle Scholar
  24. 24.
    Adkins D, Brown R, Trinkaus K, et al. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. J Clin Oncol. 1999;17:2006–14.PubMedGoogle Scholar
  25. 25.
    Cagnoni PJ, Nieto Y, Shpall E, et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol. 1998;16:1661–8.PubMedGoogle Scholar
  26. 26.
    Somlo G, Frankel P, Chow W, et al. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol. 2004;22:1839–48.PubMedCrossRefGoogle Scholar
  27. 27.
    Schwartzberg L, Weaver C, Lewkow L, et al. High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast. Bone Marrow Transplant. 1999;24:981–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Viens P, Palangie T, Janvier M, et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer. 1999;81:449–56.PubMedCrossRefGoogle Scholar
  29. 29.
    Arun B, Slack R, Gehan E, et al. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer. 1999;85:93–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Bertucci F, Tarpin C, Charafe-Jauffret E, et al. Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment. Bone Marrow Transplant. 2004;33:913–20.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Claudia Arce-Salinas
    • 1
    Email author
  • Flavia Morales-Vasquez
    • 1
  • Fernando Lara-Medina
    • 1
  • Silvia Patricia Villarreal-Colin
    • 1
  1. 1.Department of Medical OncologyInstituto Nacional de Cancerologia-MexicoTlalpan, Mexico CityMexico

Personalised recommendations